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Abstract
Introduction: The use of an automated biopsy device and real-time ultrasound
(current technology) for percutaneous renal biopsies (PRBs) has improved the
likelihood of obtaining adequate tissue for diagnosis and has reduced the
complications associated with renal biopsies. Our objective was to evaluate the
efficacy and safety of the current PRB procedure and identify possible risk factors
for the development of major complications.
Material and methods: We collected all native kidney PRBs performed with
current technology in our institute from January 1998 to April 2008. Studied
variables were collected from the patient’s chart at the time of the biopsy.
Results: We analyzed 623 (96.4%) of 646 renal biopsies performed with the
current automated procedure guided by real-time ultrasound. Although the
effectiveness was 97.6%, there were 110 complications. Fourteen (2.24%) of
these complications were major: 9 cases of renal hematoma, 2 cases with
macroscopic hematuria (which needed blood transfusion), 1 case of intestinal
perforation (which required exploratory laparotomy), 1 nephrectomy and 1 case
of a dissecting hematoma. The logistic regression analysis demonstrated the
following risk factors for developing major complications: diastolic blood pressure
≥ 90 mmHg, RR 7.6 (95% CI 1.35-43); platelet count ≤ 120 × 103/μl; 
RR 7.0 (95% CI 1.9-26.2); and blood urea nitrogen (BUN) ≥ 60 mg/dl, RR 9.27
(95% CI 2.8-30.7).
Conclusions: The observed efficacy and safety of the current technique in 
the present study were similar to observations in previous studies. Diastolic
blood pressure ≥ 90 mmHg, platelets ≤ 120 × 103/μl and BUN ≥ 60 mg/dl 
were independent risk factors for the development of major complications
following PRB. 
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Introduction
Percutaneous renal biopsy (PRB) is an essential tool for the practice of
nephrology [1]. Although the first description of a technique to perform
a PRB was published by Ball in the 1930s [2], it was not until the 1950s
that a more practical and efficient technique was clearly described by
Ibersen and Brun [3]. With the introduction of the Franklin modified Vim-
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Silverman needle in 1954 [4], obtaining kidney tissue
for proper histological diagnosis improved by 96-98%
[4-6]. Today, most hospitals perform PRBs using real-
time ultrasonography and automated percutaneous
devices [7-9]. This technique has improved safety
and increased the number of procedures that can be
performed. In addition to being an initial diagnostic
tool, real-time ultrasonography and automated
percutaneous devices can also be used to assess the
progression of renal injury and response to medical
treatment [10, 11].
For over a decade, we have performed PRB in
our institute using real-time ultrasound and an
automatic biopsy device. The first objective of this
study was to describe current native kidney PRB
indications, main histopathological diagnoses and
post-biopsy complications. Although the advantages
of the automated technique (compared with the
manual technique) have been previously demon  -
strated [12-15], many centers from deve  loping
countries continue to perform PRB with non-
automated devices and, in some cases, without
real-time ultrasound guidance. Therefore, we
compared our results using automated devices and
real-time ultrasound guidance to previously
published studies from our center that were not
performed with an automatic device and real-time
ultrasound guidance [16]. 
A series of factors has been associated with
increased risk of post-biopsy complications [17-19];
these factors include arterial hypertension,
amyloidosis, frequency of puncture, small kidneys
and bleeding diathesis, although some have not
been consistent in the literature [20, 21]. We
reviewed clinical and laboratory factors previously
related to complications with the aim of defining
potential risk factors and possible cutoff points that
may have contributed to the development of major
complications in patients who underwent real-time
ultrasound-guided PRB with an automated biopsy
device. 
Material and methods
The present series included all patients who
underwent a PRB between January 1998 and April
2008 at the Instituto Nacional de Ciencias Médicas
y Nutrición Salvador Zubirán in Mexico City. Biopsies
were performed by trained nephrology fellows using
an automated PRB device with a 16-gauge needle
(Bard Corp. NJ, USA). In addition, the fellow was
guided by real-time ultrasonography by an
experienced radiologist and supervised by
a nephrologist from the institute. 
Ideally, every patient should have normal blood
pressure (≤ 130/90 mmHg), a negative urine culture,
and normal coagulation tests (prothrombin time,
and plasma thromboplastin time in all patients and
bleeding time in cases with BUN over 50 mg/dl)
prior to the PRB. After the procedure, patients
remained hospitalized for 24 h.
The efficiency of the procedure was determined
based on the number of glomeruli obtained and
whether the nephropathologist considered the
material to be sufficient to establish a diagnosis. 
Safety was evaluated on the basis of the
presence or absence of major or minor
complications. We considered major complications
as those that required a blood transfusion, surgical
intervention and extended hospitalization, whereas
a minor complication was defined as a complication
that did not require transfusion or surgical
intervention (usually minor hematomas or transient
hematuria that resolved spontaneously and did not
prolong hospitalization over the 24-h period after
the procedure).
Patients who presented complications were
identified and classified based on whether the
complications were major or minor. Patients
identified as having major complications were
compared with the rest of the population (those
with minor complications and those who did not
present any complications) to identify potential risk
factors for major complications. We analyzed the
following independent variables: age, gender, blood
pressure at the time of the biopsy, indication for
PRB, concurrent medical conditions at the time of
the biopsy, number of shots or passes during the
procedure, histopathological diagnosis, and body
mass index. In addition, we examined the following
pre-biopsy laboratory variables: prothrombin time,
partial thromboplastin time, hemoglobin,
hematocrit, platelet count, serum creatinine, blood
urea nitrogen (BUN), and serum and urinary
albumin concentrations.
Statistical analysis
Results are expressed as frequencies
(percentage) and mean ± SD (range) for categorical
and continuous variables, respectively. For
continuous variables, such as systolic and diastolic
blood pressure, hemoglobin, prothrombin time,
thromboplastin time, platelets, serum creatinine
and BUN, the most significant cut-off points were
determined through receiver operating charac  -
teristic (ROC) curve analysis. Comparisons between
groups were performed by means of χ2 tests for
categorical data, and a logistic multivariate
regression model was used to evaluate risk factors.
The following variables were included in the logistic
regression model: age at time of biopsy
(continuous), gender (binary: female or male),
comorbidities (diabetes mellitus: 1 = yes or 2 = no;
systemic lupus erythematosus: 1 = yes or 2 = no;
liver disease: 1 = yes or 2 = no; dyslipidemia: 
1 = yes or 2 = no; and overweight/obesity: 1 = yes
or 2 = no); systolic blood pressure ≥ 140 mmHg Arch Med Sci 5, October / 2011 825
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(1 = yes or 2 = no), diastolic blood pressure 
≥ 90 mmHg (1 = yes or 2 = no), hemoglobin 
≤ 10 g/dl (1 = yes or 2 = no), prothrombin time 
≥ 12 s (1 = yes or 2 = no), thromboplastin time 
≥ 35 s (1 = yes or 2 = no), platelets ≤ 120 × 103/μl
(1 = yes or 2 = no), serum creatinine ≥ 1.5 mg/dl
(1 = yes or 2 = no), blood urea nitrogen ≥ 60 mg/dl
(1 = yes or 2 = no), number of passes ≥ 3 (1 = yes
or 2 = no). All p values were two-tailed, and the
statistical significance level was defined as p-value
< 0.05. 
Results
During the study period, 646 native kidney PRBs
were performed using an automated biopsy device
and real-time ultrasound guidance. Out of the 646
PRBs, 623 (96.4%) were analyzed and 23 were
excluded due to incomplete information in the
patient’s chart. Demographic characteristics and
laboratory findings are shown in Table I. The mean
age of the patients was 34.4 ±14.2 years, and 70.5%
of the patients were female. The most frequent
comorbidity was systemic lupus erythematosus
(45.7%). The main clinical indications that led to
a PRB were nephrotic syndrome (382 cases, 61.3%),
hematuria-proteinuria (80 cases, 12.8%), and
nephritic syndrome (56 cases, 9%) (Figure 1). 
In the present study, lupus nephritis was the
main histological finding (279 cases, 44.7%)
followed by focal segmental glomerulosclerosis
(FSGS) in 102 cases (16.4%) and 58 cases (9.3%) of
membranous nephropathy (Figure 2). The inciden  -
ces of primary glomerulopathies were as follows:
focal segmental glomerulosclerosis 16.4%, idiopathic
membranous nephropathy 9.3%, IgA nephropathy
3.3%, minimal change disease 4.9%, and crescentic
glomerulopathy 1.9%. There were 32 patients with
other histological findings: 6 cases of Henoch-
Schönlein purpura, 6 cases of membrano  -
proliferative glomerulonephritis, 3 cases of adjuvant
disease, 3 cases of normal kidney, 2 cases of
Alport’s syndrome, 2 cases of Fabry’s disease, 
Variables Total  With major  Without major  Value of p
(n = 623) complications complications 
(n = 14) (n = 609)
Female (%) 439 (70.5) 14 (100)  425 (69.8) 0.04
Age [years], mean ± SD 34.4 ±14.2 32.7 ±12.2 34.4 ±14.2 NS
Comorbidities (%)
Systemic lupus erythematosus  285 (45.7) 12 (85.7)  273 (44.8)  0.001 
Overweight/obesity (IMC > 27 kg/m2)  190 (30.5) 2 (14.3)  188 (30.9)  NS
Arterial hypertension  168 (27.1) 4 (28.6)  164 (27)  NS
Dyslipidemia  83 (13.4) 1 (7.1)  82 (13.5)  NS
Diabetes mellitus 41 (6.6) 0 (0)  41 (6.8)  NS
Liver disease 8 (1.3) 0 (0) 8 (1.3) NS
Pre-biopsy laboratories (mean ± SD) 
Hemoglobin [g/dl] 12.2 ±2.5 10.1 ±2.1 12.2 ±2.4 < 0.001 
(max-min) (6.3-19.1) (7.6-15) (6.3-19.1)
Platelets (× 103/μl) 281 ±112 207.9 ±106 283 ±112.4 0.009 
(max-min) (51-957) (92-424) (51-957)
Prothrombin time [s] 10.1 ±1.5 10.1 ±1.9 10.2 ±2.9 NS 
(max-min) (4-15.9) (4-15.9) (9-12.8)
Thromboplastin time [s] 29.4 ±4.5 30.3 ±6.1 29.8 ±7.5 NS 
(max-min) (20-46) (22-39) (20-46) 
Serum creatinine [mg/dl] 1.7 ±1.5 2.1 ±0.86 1.7 ±1.5 0.018 
(max-min) (0.1-13) (0.9-3.2) (0.1-13)
Blood urea nitrogen [mg/dl] 29.4 ±22.3 56.5 ±28.2 28.7 ±21.7 < 0.001 
(max-min) (3.1-137) (16-98.4) (3.1-137)
Serum albumin [g/dl] 2.4 ±0.91 1.87 ±0.59 2.47 ±0.90  0.031 
(max-min) (0.6-4.8) (1-2) (0.6-4.2)
Albuminuria [g/day] 6.0 ±5.1 4.9 ±3.03 6.1 ±5.2 NS
(max-min) (0.1-39) (0.21-10.8) (0.1-39)
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2 cases of dense deposit disease and 1 case of each
of the following diagnoses: plasma cell dyscrasia,
renal infiltration by leukemia, thin membrane
disease, glomerulopathy linked to POEMS syndrome
(polyneuropathy, organomegaly, endocrinopathy,
monoclonal gammopathy, and skin changes),
lecithin-cholesterol acyltransferase (LCAT) deficiency,
idiopathic nodular glomerulosclerosis, nephropathy
linked to the human immunodeficiency virus and
immunotactoid glomerulonephritis. 
Although 285 patients had a clinical diagnosis of
lupus, we only confirmed the histological diagnosis
of lupus in 279 patients and the rest had some other
histological findings described above. According to
the ISN/RPS lupus nephritis histological classification,
the varieties of lupus nephritis among the 279
patients were diffuse proliferative glomerulonephritis
type IV (46%, 129/279), focal proliferative glome  -
rulonephritis type III (17%, 48/279), membranous
glomerulonephritis type V (14%, 38/279), and the
mesangial variety type II (5%, 14/279). In addition,
combined histopathological forms were diagnosed:
7% (19/279) of cases had features of types III and V,
and 6% (16/279) presented features of types IV and V.
Unsuccessful biopsy
Necrotic glomerulonephritis
Amyloidosis
Sclerosis glomerular
Tubulointerstitial nephritis
Diabetes mellitus
IgA nephropathy
Mesangiocapillar nephritis
Minimal changes disease
Others
Membranous glomerulopathy
Focal segmental glomerulosclerosis
Nephritis lupus
0 5 10 15 20 25 30 35 40 45 50
%
Figure 1. The most frequent biopsy indications of our series (1998 to 2008)
Macroscopic hematuria
No report
Subnephrotic proteinuria
Rapidly progressive glomerulonephitis
Chronic glomerulopathy
Nephritis syndrome
Proteinuria-hematuria
Nephrotic syndrome
01 0 2 0 3 0 4 0 5 0 6 0 7 0
%
Figure 2. The most frequent histological findings of our series (1998 to 2008)Arch Med Sci 5, October / 2011 827
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Safety evaluation
The present study observed a total of 110
complications (17.6%). Among these complications,
96 (15.24%) were minor and 14 (2.24%) were major.
The most frequent minor complication was the
presence of an ultrasound-detected hematoma,
which occurred in 87 cases (13.9%), followed by
transient hematuria in 8 cases (1.2%), which did not
require transfusion. A major hematoma requiring
blood transfusion (n = 9, 1.4% of the total popu  -
lation) was the most common major complication.
In addition, we observed hematuria requiring
transfusion in 2 cases (0.3% of the total population).
Moreover, selective embolization secondary to
hematoma, nephrectomy and intestinal perforation
were each observed in one case (each complication
accounted for 0.16% of the total population). 
Efficiency evaluation
In our study, of 623 biopsies analyzed, there were
608 biopsies (97.5%) with an adequate sample
(representative) to establish the histopathological
diagnosis. Of these, 468 biopsies had more than 
10 glomeruli (76.9%), 110 biopsies had 6 to 
10 glomeruli (18.1%), and 30 biopsies had 1 to 
5 glomeruli (5%). There were five procedures with
inadequate or insufficient histological material to
establish a diagnosis, and ten procedures were
considered unsuccessful because no renal tissue
was obtained. 
Risk factors for major complications 
We investigated the risk factors associated with
the development of major complications in
procedures using the automated PRB device by
comparing patients who developed major
complications (n = 14) with patients who did not
present major complications (n = 609). As a result
of the univariate analysis, the following variables
were found to be significantly associated with
major complications: female gender, systemic lupus
erythematosus, diastolic blood pressure ≥ 90 mmHg,
hemoglobin  ≤ 10 g/dl, prothrombin time 
≥ 12 s, number of platelets ≤ 120 × 103/μl, serum
creatinine  ≥ 1.5 mg/dl, and BUN ≥ 60 mg/dl
(Table II). However, in the logistic multivariable
regression analysis, only the following variables were
found to have an independent effect: diastolic blood
pressure ≥ 90 mmHg, RR 7.6 (95% CI 1.35-43.12,
p = 0.021); platelets ≤ 120 × 103/μl, RR 7.0 (95% CI
1.92-26.24, p = 0.003); and serum BUN ≥ 60 mg/dl,
RR 9.27 (95% CI 2.80-30.7, p < 0.01).
Discussion 
Our data show the safety/efficacy profile of real-
time ultrasound for percutaneous renal biopsies
(PRBs) by analyzing 623 consecutive procedures
Variable With major  Without major RR 95% CI Value of p
complications complications
(n = 14) (n = 609)
Female (%) 14 (100) 425 (69.8) 6.6 0.9-49.8 0.03
Arterial hypertension (%) 4 (28.6) 164 (27) 1.2 0.4-3.6 1.00
Diabetes mellitus (%) 0 (0) 41 (6.8) 0.9 0.9-1.0 0.62
Systemic lupus erythematosus (%) 12 (85.7) 298 (49.1) 4.8 1.38-17.1 0.007
Dyslipidemia (%) 1 (7.1) 82 (13.5) 0.4 0.05-3.0 0.72
Liver diseases (%) 0 (0) 8 (1.3) 0.9 0.9-1.0 1.00
Overweight/obesity (%)  2 (14.3) 188 (30.9) 0.5 0.13-1.69 0.30
Systolic blood pressure ≥ 140 mmHg (%) 3 (21.4) 85 (14.4) 0.5 0.18-1.66 0.29
Diastolic blood pressure ≥ 90 mmHg (%) 2 (14.3) 11 (1.9) 5.2 1.9-13.9 0.04
Hemoglobin ≤ 10 g/dl (%) 8 (57.1) 131 (21.8) 4.9 1.88-12.5 0.001
Prothrombin time ≥ 12 s (%) 5 (41.7) 65 (11.9) 4.7 1.5-14.4 0.013
Thromboplastin time ≥ 35 s (%) 4 (28.6) 83 (15.2) 2.0 0.62-6.48 0.27
Platelets ≤ 120 × 103/μl (%) 4 (28.6) 21 (3.5) 12.1 3.8-37.5 < 0.01
Serum creatinine ≥ 1.5 mg/dl (%) 10 (7.4) 225 (37.2) 4.1 1.4-11.7 0.009
Blood urea nitrogen ≥ 60 mg/dl (%) 7 (50) 53 (8.9) 9.3 3.42-25.0 < 0.01
Number of passes¥ ≥ 3 (%) 1 (7.7) 9 (1.5) 5.3 0.62-45.5 0.199
Table II. Univariate analysis of risk factors for major complications
¥ Number of passes: number of times that the needle penetrates the kidney tissue828 Arch Med Sci 5, October / 2011
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performed from January 1998 to April 2008. In line
with other previously published series, effectiveness
was 97.6%, with a 2.24% rate of major complications
[21-23]. Our institute is a reference center for lupus
erythematosus, which explains the high prevalence
of lupus erythematosus diagnosis and a relatively
young population, most of whom had nephrotic
syndrome. In Table III, we compared the
histopathological diagnoses of the present study
with those of other large native kidney PRB series
[24-29]. Our population displayed a low frequency
of IgA nephropathy, which was not entirely
surprising because patients in our institute with
a history of occasional macroscopic hematuria,
microscopic hematuria or, in some cases, additional
low grade proteinuria are often observed and treated
in the outpatient clinic. Indeed, these patients were
only considered for PRB if the procedure was clearly
justified, such as cases involving increasing
proteinuria or serum creatinine [30]. 
In this series, the efficiency of the automated
technique was similar to that of most other
published series [12, 15], and the procedure was
found to be relatively safe. Indeed, the frequency
of major complications was only 2.24%, which was
similar to, or even lower than, the frequencies seen
with other invasive procedures, for example
subclavian catheter placement (1.03%), diagnostic
endoscopy (1.71%), liver biopsy (2.8%), and general
anesthesia in patients with ASA I-II (0.59%) [16].
Whittier and Korbet examined 750 patients and
found that 48 patients developed major
complications (6.4%). Out of these patients, the
majority required a blood transfusion, although
there were two deaths directly related to PRB. In
our series, 11 patients (1.7%) required a blood
transfusion, and there were no reported deaths.
Nevertheless, 3 patients (0.48%) required an
invasive intervention as a result of the procedure,
which was slightly less than the percentage
reported by Whittier and Korbet [21]. In the present
series, we observed one case of intestinal
perforation (0.16%), which was adequately
managed with surgery, similar at reported by
Rasheed et al. in a series of 104 pediatric patients
who underwent PRB, who only reported one case
of intestinal perforation (0.96%) [31]. The frequency
of nephrectomy linked to the PRB procedure has
been variable between studies. For example, Manno
et al. reported an incidence of post-biopsy nephrec  -
tomy of 0.26% [32], discreetly major compared with
0.16% in our series.
We compared the efficiency and safety of the
current series (using real-time ultrasound guidance
and an automated biopsy device) with a previous
series of patients who underwent PRBs with
a manual technique (1,005 biopsies) from January
1970 to March 1996 [16]. The comparison of the two
techniques demonstrated a significant increase in
efficacy with the current technique (Table IV). We
believe that the improvement in the effectiveness
using real time ultrasound was associated with the
certainty of obtaining renal tissue due to the direct
vision of the kidney at the time of puncture, while
in the manual technique such certainty is lacking
and up to 25% of the biopsies do not have enough
material for diagnosis [16]. On the other hand,
within the concept of efficiency some authors
consider representative biopsy, when between 
8 and 10 glomeruli per sample are obtained; however,
others consider representative biopsy those with
which it is possible to make a histological diagnosis
[33]. There is no general consensus yet on the
number of glomeruli needed to make the diagnosis,
because this number varies from one for diffuse
nephropathies to 25 for focal nephropathies 
[34, 35]. However, data analysis using the number
of glomeruli as a definition of efficiency may not
be appropriate because, as commented previously,
in many cases the diagnosis can be made with less
than 8 glomeruli, provided histological lesions are
representative for a particular disease [33, 34].
Author (reference) Center N PGN† FSGS‡ MesGπ IgAN¥ MPG
¶ MG†† GS‡‡ MCD¥¥
Dragovic et al. [24] New York, USA 299 57.6 37.8 – 27.3 – 16.6 – 9.1
Malafronte et al. [25] Sao Paolo, Brazil 1,844 54.2 29.7 3.8 17.8 7 20.7 4.1 9.1
Covic et al. [26] Bucharest, Romania 635 66.2 11.5 28.9 – 29.4 11.2 7.9 8.5
Pacini et al. [27] Pisa, Italy 3,269 66 19.8 45.7 – – 23 – 5.3
Chang et al. [28] Seoul, Korea 1,818 85.2 5.6 – 28.3 4 12.3 – 15.5
Kazi et al. [29] Karachi, Pakistan 316 – 39.8 – 2.5 4.1 26.5 – 14.8
Torres et al.  Mexico City, Mexico 623 39.3 16.4 3.5 3.3 – 9.3 1.9 4.9
(current study)
Table III. Comparison of the main histological findings among different series of published studies
Results are presented in percentages. †PGN – primary glomerulonephropathies, ‡FSGS – focal segmental glomerulosclerosis, πMesG – mesangial
glomerulonephritis (not IgA), ¥IgAN – IgA nephropathy, ¶MPG – mesangioproliferative, ††membranous glomerulopathy, ‡‡GS – glomerular sclerosis,
¥¥MCD – minimal change diseaseArch Med Sci 5, October / 2011 829
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Surprisingly, we also observed a significant
increase in the incidence of minor complications
with the current automated and ultrasound-guided
technique. We think that this observation was likely
caused by the use of ultrasound monitoring after
the procedure in all patients of the present series
because the patients of the previous series were
not subjected to ultrasound monitoring, and only
those who had a clinically relevant event were
studied. Generally our safety results were not
different from other comparable large series 
[35-39], except for our lower rate of minor
complications compared with Eiro et al. [36] and
a higher frequency of major complications
compared with studies by Donovan et al. and
Hergesell et al. [37, 38]. Moreover, within the major
complications, there was no statistically significant
difference when comparing the two groups in our
population.
The analysis of risk factors demonstrated
a statistically significant risk of major complications
with the presence of high diastolic blood pressure,
a low platelet count, and a high serum BUN.
A diastolic blood pressure of ≥ 90 mmHg increased
the risk of major complications similarly to results
described more than 10 years ago by Diaz-Buxo and
Donadio [23]. In the same way, Eiro et al. showed
that hypertension (systolic blood pressure > 140
mmHg or diastolic blood pressure and > 90 mmHg)
was an independent risk factor for post-biopsy
bleeding [36]. In our case, the mechanism by which
diastolic hypertension increases the development
of major complications perhaps is related to the
known association of diastolic hypertension and
the development of microbleeds [40], which
associated with renal puncture per se may increase
the risk of developing major bleeding [32, 33, 41]. 
Our study showed that patients with a platelet
count of ≤ 120 × 103/μl had an increased risk of
complications. In addition, a platelet count of less
than 70,000 U/dl has previously been shown to be
associated with increased bleeding complications
in hepatic biopsies [21]. A value (cut-off point) for
a safe platelet count in PRB, however, has not been
established. Because our PRB protocol did not
include the routine evaluation of bleeding time, it
was not possible to assess this variable as
a potential risk factor. Furthermore, the univariate
analysis showed a statistical link to complications
in patients with prothrombin time (PT) ≥ 12 s, but
this association was not sustained in the
multivariate analysis.
In the present study, we observed a significant
increase in the number of complications in patients
with BUN levels ≥ 60 mg/dl. This finding could be
related to the role of uremia in platelet dysfunction.
An in vitro study showed that an increase in urea
nitrogen altered the platelet aggregation process
[42], and clinical studies have suggested that there
is an increased risk of developing a hemorrhagic
complication after PRB in patients with uremic
syndrome [42, 43]. Although other studies have
demonstrated an association between serum
creatinine levels and complications [18, 44], our
study was unable to prove this association. In
addition, we were unable to confirm a link between
the number of shots and passes with development
of major complications.
Currently, technical advances have made PRB
a safe outpatient procedure and have been used to
diminish costs [22, 45]. In relation to the time of
hospitalization, some authors recommend that
patients be hospitalized overnight [38, 46]. In our
series, all of the complications presented within the
first 6 h of observation, and another study showed
that complications were evident within the first 
3 h [47]. We believe that these findings support the
concept that PRBs could safely be performed in an
outpatient setting [47, 48].
On the other hand, an important factor to
consider in assessing the invasive procedures is the
skills and experience of the physician performing
the procedure. As described in the methodology, in
our hospital most biopsies are made by residents
under the supervision of a nephrologist; therefore,
it is possible that there is a potential learning curve
effect associated with the safety and efficacy of the
procedure. However, due to the retrospective nature
of our study, we cannot know with certainty that
Parameter Michaca et al.,T orres et al., Toledo et al., Castro et al., Donovan et al., Eiro et al.,H ergesell et al.,
México México Spain Portugal England Japan Germany
(manual)( automated)( automated)( automated)( automated)( automated)( automated)
(n = 1,005) (n = 623) (n = 797) (n = 91) (n = 192) (n = 394) (n = 1090)
Efficacy [%] 88.7  97.6 – 92.3 97.8 98.5 98.8
Safety [%] 
Minor 8.65 15.4 13.2 9.8 – 58.6 7.5
complications
Major 2.48 2.24 0.75 4.3 0 0 0.3
complications
Table IV. Comparison of the efficacy and safety of percutaneous renal biopsy techniques (manual versus automated)830 Arch Med Sci 5, October / 2011
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information, which is a weakness of our work and
we will try to study it in a future cohort.
In conclusion, use of the current PRB technique
in our study resulted in similar levels of efficacy and
safety as previous studies. The benefits of this new
technique should be reported so that many
healthcare centers in developing countries could
consider using an automated biopsy device with
real-time ultrasound. We revealed a number of
independent risk factors for the development of
major complications – diastolic blood pressure ≥ 90
mmHg, platelets ≤ 120 × 103/μl and BUN ≥ 60 mg/dl
– that must be taken into account to reduce the
frequency of major complications.
References
1. Schwartz MM, Korbert SM, Lewis EJ. The value of the renal
biopsy. In: Contemporary issues in nephrology. Narins RG,
Stein JN (eds). New York, Churchill Livingstone 1992; 
269-304.
2. Ball RP . Needle (aspiration) biopsy. Tenn State Med Ass J
1934; 27: 203.
3.  Iversen P, Brun C. Aspiration biopsy of the kidney. 
Am J Med 1951; 11: 324-30.
4. Kark RM, Muehrcke RC, Pirani CL. Biopsy of the kidney in
the in the prone position. Lancet 1954; 1047-9.
5.  Muehrcke RC, Kark RM, Pirani CL. Technique of
percutaneous renal biopsy in the prone position. J Urol
1955; 74: 267-77.
6. Kark RM, Muehrcke RC, Pollak VE, et al. An analysis of
500 percutaneous renal biopsies. Arch Intern Med 1958;
101: 439-51.
7. Donnelly S, Goodyer P, Mauer M; RASS Investigators.
Comparing the automated versus manual method of
needle biopsy for renal histology Artefacts. Nephrol Dial
Transplant 2008; 23: 2098-100.
8. Doyle AJ, Gregory MC, Terreros DA. Percutaneous native
renal biopsy: comparison of a 1.2 mm spring-loaded
system with a traditional 2 mm hand-driven system. Am
J Kidney Dis 1994; 23: 498-503.
9. Dohun K, Heungsoo K, Gyutae S, et al. A randomized,
prospective, comparative study of manual and automated
renal biopsies. Am J Kidney Dis 1998; 32: 426-31.
10. Nass K, O´Neill WC. Bedside renal biopsy: ultrasound
guidance by the nephrologist. Am J Kidney Dis 1999; 34:
955-9.
11.  Birnholz JC, Kasinath BS, Corwin HL. An improved
technique for ultrasound guided percutaneous renal
biopsy. Kidney Int 1985; 27: 80-2.
12. Tang S, Li JH, Lui S. Free-hand, ultrasound-guided
percutaneous renal biopsy: experience from a single
operator. Europ J Radiol 2002; 4: 65-9.
13. Ori Y, Neuman H, Chagnac A, et al. Using the automated
biopsy gun with real-time ultra-sound for native renal
biopsy. Isr Med Assoc J 2002; 4: 698-701. 
14. Korbert SM. Percutaneous renal biopsy. Semin Nephrol
2002; 22: 254-67.
15. Kim D, Kim H, Shin G, et al. A randomized, prospective,
comparative study of manual and automated renal biopsy.
Am J Kidney Dis 1998; 32: 426-31.
16. Burstein DM, Korbert SM, Schwartz MM. The use of the
automatic core biopsy system in percutaneous renal
biopsy: a comparative study. Am J Kidney Dis 1993; 22:
545-52.
17. Feneberg R, Schaefer F, Zieger B, et al. Percutaneous renal
biopsy in children: a 27-year experience. Nephron 1998;
79: 438-46.
18. Health and Public Policy Committee, American College of
Physicians: Clinical Competence in Percutaneous Renal
Biopsy. Ann Intern Med 1988; 108: 301-3.
19. Salama AD, Renal biopsy. Medicine 2007; 35: 383-5.
20. Whittier WL, Korbet SM. Renal biopsy: update. Curr Opin
Nephrol Hypertens 2004; 13: 661-5.
21.  Khajehdehi P, Junaid SM, Salinas-Madrigal L, et al.
Percutaneous renal biopsy in the 1990´s: safety, value and
implications for early hospital discharge. Am J Kidney Dis
1999; 34: 92-7.
22. Diaz-Buxo JA, Donadio JV. Complications of percutaneous
renal biopsy: an analysis of 1, 000 consecutive biopsies.
Clin Nephrol 1975; 4: 223-7.
23. Dragovic D, Rosenstock JL, Wahl SJ, Panagopoulos G,
DeVita MV, Michelis MF. Increasing incidence of focal
segmental glomerulosclerosis and an examination of
demographic patterns. Clin Nephrol 2005; 63: 1-7.
24. Malafronte P, Mastroianni-Kirsztajn G, Betônico GN, 
et al. Paulista Registry of glomerulonephritis: 5-year data
report. Nephrol Dial Transplant 2006; 21: 3098-105. 
25. Covic A, Schiller A, Volovat C, et al. Epidemiology of renal
disease in Romania: a 10 year review of two regional renal
biopsy databases. Nephrol Dial Transplant 2006; 21: 
419-24.
26. Panichi V, Pasquariello A, Innocenti M, et al. The Pisa
experience of renal biopsies, 1977-2005. J Nephrol 2007;
20: 329-35.
27. Chang JH, Kim DK, Kim HW, et al. Changing prevalence
of glomerular diseases in Korean adults: a review of 20
years of experience. Nephrol Dial Transplant 2009; 24:
2406-10. 
28. Kazi JI, Mubarak M, Ahmed E, Akhter F, Naqvi SA, Rizvi
SA. Spectrum of glomerulonephritides in adults with
nephrotic syndrome in Pakistan. Clin Exp Nephrol 2009;
13: 38-43.
29. D’Amico G. The commonest glomerulonephritis in the
world: IgA nephropathy. Q J Med 2001; 64: 709-27.
30. Rasheed SA, Mugeiren MA, Abdurrahman MB, Elidrissy
AT. The outcomes of percutaneous renal biopsy in
children: an analysis of 120 consecutive cases. Ped
Nephrology 1990; 6: 600-3.
31. Manno C, Strippoli GF, Arnesano L, et al. Predictors of
bleeding complications in percutaneous ultrasound-guided
renal biopsy. Kidney Intern 2004; 66: 1570-7.
32. Madaio MP . Renal biopsy. Kidney Int 1990; 38: 529-43.
33. Cotwn'i HL, Schwartz MM, Lewis EJ. The importance of
sample size in the interpretation of renal biopsy. 
Am J Nephrol 1988; 8: 85-9.
34. Michaca LG, Chew-Wong A, Sotelo L, Gamba G, Correa-
Rotter R. Biopsia renal percutánea: Análisis de 26 an
~os,
tasa de complicaciones y factores de riesgo. Revista de
Investigación Clínica 52: 125-31.
35. Castro R, Roquete P, Silvestre F, Morgado T. Percutaneous
kidney biopsy: eight years-experience. Acta Med Port
2004; 17: 20-6. 
36. Eiro M, Katoh T, Watanabe T. Risk factors for bleeding
complications in percutaneous renal biopsy. Clin Exp
Nephrol 2005; 9: 40-5.
37. Donovan KL, Thomas DM, Wheeler DC, Macdougall IC,
Williams JD. Experience with a new method for
percutaneous renal biopsy. Nephrol Dial Transplant 1991;
6: 731-3.
38. Hergesell O, Felten H, Andrassy K, Kühn K, Ritz E. Safety
of ultrasound-guided percutaneous renal biopsy-Arch Med Sci 5, October / 2011 831
Percutaneous renal biopsy of native kidneys: efficiency, safety and risk factors associated with major complications
retrospective analysis of 1090 consecutive cases. Nephrol
Dial Transplant 1998; 13: 975-7.
39. Toledo K, Pérez MJ, Espinosa M, et al. Complications
associated with percutaneous renal biopsy in Spain, 50
years later. Nefrología 2010; 30: 539-43.
40. Whittier WI, Korbet SM. Timing of complications in
percutaneus renal biopsy. J Am Soc Nephrol 2004; 15: 
142-7.
41. Naganuma T, Takemoto Y, Yamasaki T, et al. Factors
associated with silent cerebral microbleeds in
hemodialysis patients. Clin Nephrol 2011; 75: 346-55.
42. Steiner RW, Coggins C, Carvalho ACA. Bleeding time in
uremia: a useful test to assess clinical bleeding. 
Am J Hematol 1979; 7: 107-17.
43. Shidam GB, Siddiqi N, Beres JA, et al. Clinical risk factors
associated with bleeding after native kidney biopsy.
Nephrology 2005; 10: 305-10.
44. Parrish AE. Complications of percutaneous renal biopsy:
a review of 37 years experience. Clin Nephrol 1992; 38:
135-41.
45. Fraiser I, Fairley K. Renal biopsy as an outpatient
procedure. Am J Kidney Dis 1995; 25: 876-8.
46. Nelson CL, Mackinnon MW, Charlesworrth JA. Importance
of renal biopsy. Nephrology 2001; 6: 270-3.
47. Al-Hweish AK, Abdul-Rehaman IS. Outpatient percu  -
taneous renal biopsy in adult patients. Saudi J Kidney Dis
Transplant 2007; 18: 541-6.
48. Mahajan V, Suri D, Saxena A, Nada R. Should ultrasound
guided percutaneous renal biopsy in children be done in
a day care setting? Indian J Nephrol 2010; 20: 21-4.